Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

BACKGROUND: Treatment options for metastatic colorectal cancer (CRC) are limited after a fluoropyrimi-dine, oxaliplatin and irinotecan; novel agents need to be explored in this setting. Dasatinib, an oral inhibitor of Src family kinases, inhibits proliferation in CRC cell lines and has antitumor act...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Sharma, Manish R., Wroblewski, Kristen, Polite, Blase N., Knost, James A., Wallace, James A., Modi, Sanjiv, Sleckman, Bethany G., Taber, David, Vokes, Everett E., Stadler, Walter M., Kindler, Hedy L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4317401/
https://ncbi.nlm.nih.gov/pubmed/21552992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9681-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados